Research has generally shown that it improves insulin sensitivity by either prolonging its activity or up-regulating the production of mRNA to produce more insulin receptors. A 2013 Cochrane review was unable to find "reliable evidence to inform firm decisions" to support such claims. History Ī study in 1989 suggested that chromium(III) picolinate may assist in weight loss and increase muscle mass which led to an increase in the usage of chromium(III) picolinate supplements, resulting in it being for a while the second most widely used supplement behind calcium.
As such, chromium(III) picolinate has been proposed as a treatment for type 2 diabetes, although its effectiveness remains controversial due to conflicting evidence from human trials. Chromium has been identified as regulating insulin by increasing the sensitivity of the insulin receptor. Large quantities of chromium are needed for glucose utilization by insulin in normal health, but deficiency is extremely uncommon and has been observed usually in people receiving 100% of their nutrient needs intravenously, i.e., total parenteral nutrition diets.
This bright-red coordination compound is derived from chromium(III) and picolinic acid. It is sold as a nutritional supplement to treat type 2 diabetes and promote weight loss. Chromium(III) picolinate is a chemical compound with the formula Cr(C 5H 4N(CO 2H)) 3, commonly abbreviated as CrPic 3.
0 kommentar(er)
